Navigation Links
Epizyme to Partner to Develop DOT1L Companion Diagnostic
Date:4/18/2013

CAMBRIDGE, Mass., April 18, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676, Epizyme's most advanced clinical product candidate, is an inhibitor targeting the DOT1L histone methyltransferase (HMT) for the treatment of mixed lineage leukemia (MLL-r), an aggressive genetically defined subtype of the two most common forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Under the agreement, Abbott will utilize its proprietary fluorescence in situ hybridization (FISH) technology to design a test to detect MLL genetic alterations that lead to the oncogenic (cancer causing) function of DOT1L. Epizyme will use Abbott's FISH-based test to help identify eligible patients for its DOT1L inhibitor.

About mixed lineage leukemia (MLL-r)
MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), caused by a chromosomal translocation involving the MLL gene. Based on published research, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. MLL-r occurs in both an adult population and an infant/pediatric population. At this time, there are no approved therapies specifically indicated for MLL-r.

About Epizyme, Inc.
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme has entered into therapeutic collaborations with Celgene, Eisai and GSK that have provided it with approximately $120 million in non-equity funding through December 31, 2012. 

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.


'/>"/>
SOURCE Epizyme
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme to Present at Upcoming Conferences in February
2. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
3. Tria Beauty, Inc. and Ulta Announce New Retail Partnership
4. Richard Atkin to Join MedTech Nordic Investing & Partnering 2013
5. RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals Interventional Products Business
6. Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials
7. Core Informatics and OpenEye Scientific Software Forge Partnership
8. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
9. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
10. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today
11. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
(Date:3/27/2017)... , March 27, 2017 ... as the NASDAQ Composite closed the trading session up ... and the S&P 500 was down 0.08%. US markets ... sectors finishing the day in green. Pre-market today, Stock-Callers.com ... Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), ...
(Date:3/27/2017)... March 27, 2017 Cota Healthcare, ... value-based precision medicine, today announced the signing ... Pharmaceuticals Corporation to help improve clinical and ... As part of this agreement, which ... entered into January 2016, teams from across ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 2017 , ... American Veterinarian™, the leading multimedia provider and ... the launch of Veterinarian’s Money Digest™, a business and financial resource for veterinary ... Veterinarian™. , “We look forward to launching Veterinarian’s Money Digest™,” said ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... The comprehensive weight management program at Women’s Excellence will help patients lose weight ... and physical exam. The specialists at Women's Excellence will measure BMI, body ...
(Date:3/27/2017)... NY (PRWEB) , ... March 27, 2017 , ... ... in epigenetic research products enables researchers to pursue the recent RNA methylation “gold ... methylation . In light of the newfound characteristics of N6-methyladenosine, or m6A ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare and ... hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide ... and value analysis professionals have a ‘seat at the table’ with clinical committees ...
(Date:3/27/2017)... Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... men with prostate cancer, including all stages, is more than 95%. Once the cancer ... drastically to less than 30%. To find out how to avoid this latter group, ...
Breaking Medicine News(10 mins):